Indivior Raises 2025 Guidance After Strong Q2 Results

Indivior ( (INDV) ) has issued an update.

On July 31, 2025, Indivior reported its second-quarter financial results, showing a total net revenue of $302 million, with SUBLOCADE net revenue increasing by 9% year-over-year. The company raised its full-year 2025 financial guidance due to better-than-expected performance, with expectations for total net revenue and adjusted EBITDA increasing significantly. Indivior is implementing Phase 1 of its Action Agenda to grow U.S. SUBLOCADE revenue and streamline operations, positioning itself for future growth. The company also announced its inclusion in the Russell Equity Indexes and completed its transition to trading exclusively on Nasdaq.

The most recent analyst rating on (INDV) stock is a Buy with a $1400.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Spark’s Take on INDV Stock

According to Spark, TipRanks’ AI Analyst, INDV is a Outperform.

Indivior’s strong technical performance and improving financial trajectory are tempered by valuation concerns and recent revenue challenges. The company’s strategic initiatives and market position offer potential for recovery, but investors should be cautious of overbought signals and balance sheet weaknesses.

To see Spark’s full report on INDV stock, click here.

More about Indivior

Indivior PLC is a pharmaceutical company primarily focused on developing medications for the treatment of opioid use disorder (OUD). Its key products include SUBLOCADE, an extended-release buprenorphine injection, and SUBOXONE Film, used for opioid addiction treatment. The company is committed to advancing treatment options and has a strong market focus in the United States.

Average Trading Volume: 1,838,684

Technical Sentiment Signal: Buy

Current Market Cap: $2.16B

For detailed information about INDV stock, go to TipRanks’ Stock Analysis page.